26228-95-5

Upstream product

• 675-20-7 piperidin-2-one 
• 756874-11-0 5-methoxycarbonylamino-valeric acid 
• 660-88-8 5-aminopentanoic acid 
• 34433-86-8 3-bromo-2-piperidinone 

Downstream Products

• 34433-86-8 3-bromo-2-piperidinone 
• 1571062-21-9 (E)-3-bromo-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridine-2(1H)-one 
• 1571062-22-0 (E)-3-bromo-1-(2-methyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridine-2(1H)-one 
• 1571062-23-1 (E)-3-bromo-1-(2-ethyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridine-2(1H)-one 
• 1571062-24-2 (E)-3-bromo-1-(2-propyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridine-2(1H)-one 
• 1571062-25-3 (E)-3-bromo-1-(2-butyl-3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridine-2(1H)-one 
• 614754-01-7 2-oxopiperidin-3-yl acetate 

Relevant academic research and scientific papers

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

Synthesis method of valerolactam alkaloid compound (by machine translation)

The invention discloses a synthesis method, of a valerolactam alkaloid compound. Comprising: 1) reacting thionyl chloride with methanol, then adding ferulic acid, synthesizing ferulic acid methyl ester; 2) reacting 2 -nitrogen hexanone with phosphorus pentachloride; 4) 3, 3 -dibromo -2 - azaltrexone reacts with hydrogen and sodium acetate under the action of potassium iodide to generate 3-bromo 3 -cyclohexanone; 3) reaction, and reacting with hydrogen -2 - and sodium acetate under the action of potassium iodide; and the like 3 -2 . 5) 4) The terpineol prepared in step 3 -) is reacted, with sodium hydroxide, with the terpineol prepared in step -2 2 -) to form a lactam alkaloid compound. The synthetic method has the advantages of accessible raw material sources, mild reaction conditions, and simple reaction process operation. (by machine translation)

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo

Piperlongumine 1 increases reactive oxygen species (ROS) levels and preferably induces cancer cell apoptosis by triggering different pathways. However, the poor solubility of 1 limits its intensive investigation and clinical application. Ligustrazine possesses a water-soluble pyrazine skeleton and can inhibit proliferation and metastasis of cancer cells. We synthesized compound 3 by replacement of the trimethoxyphenyl of 1 with ligustrazine moiety and further introduced 2-Cl, -Br, and -I to 3 for synthesis of 4-6, respectively. Compound 4 possessed 14-fold greater aqueous solubility than 1 and increased ROS levels in colorectal cancer HCT-116 cells. Additionally, 4 preferably inhibited proliferation, migration, invasion, and heteroadhesion of HCT-116 cells. Treatment with 4 suppressed tumor growth and lung metastasis in vivo and prolonged the survival of tumor-bearing mice. Furthermore, 4 mitigated TGF-β1-induced epithelial-mesenchymal transition and Wnt/β-catenin activation by inhibiting the Akt and GSK-3β phosphorylation in HCT-116 cells. Collectively, 4 displayed significant antiproliferation and antimetastasis activities, superior to 1.

Thieno [3, 2 - c] pyridine compound, its preparation method and application

The invention relates to a thieno-[3,2-c] pyridine type compound and an application thereof. The compound has a structure shown by a formula (I) in the specification. The compound of which the structure is shown by the formula (I), provided by the invention has a very good effect of inhibiting the activity of Bruton kinase. The invention also relates to the application of the compound in preventing and/or treating diseases which are improved by virtue of BTK (Bruton tyrosine kinase) activity inhibition.

Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells

Piperlongumine (PL) is a natural alkaloid with broad biological activities. Twelve analogues have been designed and synthesized with non-substituted benzyl rings or heterocycles in this work. Most of the compounds showed better anticancer activities than the parent PL without apparent toxicity in normal cells. Elevation of cellular ROS levels was one of the main anticancer mechanisms of these compounds. Cell apoptosis and cell cycle arrest for the best compound ZM90 were evaluated and similar mechanism of action with PL was demonstrated. The SAR was also characterized, providing worthy directions for further optimization of PL compounds.

CA amide analogs and its preparation method and application

The invention relates to the technical field of medicines. Piplartine is alkaloid extracted from perennial herbaceous vine piper longum of piperaceae. The invention provides a Piplartine analogue, which comprises a cis-trans-isomer, and any arbitrary mixture in those forms or medicinal salt thereof, and the structural formula of the Piplartine analogue is shown in a general formula (I). The invention also provides a preparation method of substituted Piplartine compounds, and an application thereof in preparation of an antitumor medicament.

Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one Derivatives as Potential Hsp90 Inhibitors

A novel class of 5,6-dihydro-4H-benzo[d]isoxazol-7-ones and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-ones was designed, synthesized, and assayed to investigate the affinity toward Hsp90 protein. The synthetic route was based on a 1,3-dipolar cycloaddition of nitriloxides, generated in situ from suitable benzaldoximes, with 2-bromocyclohex-2-enones or 3-bromo-5,6-dihydro-1H-pyridin-2-ones. Whereas all the compounds bearing a benzamide group on the bicyclic scaffold were devoid of activity, the derivatives carrying a resorcinol-like fragment showed a remarkable inhibitory effect on Hsp90. Docking calculations were performed to investigate the orientation of the new compounds within the binding site of the enzyme. A series of 5,6-dihydro-4H-benzo[d]isoxazol-7-ones and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-ones was designed, synthesized, and assayed to investigate affinity toward Hsp90 protein. Compounds carrying a resorcinol-like fragment showed a remarkable inhibitory effect on Hsp90. Docking calculations were performed to investigate the orientation of the new compounds within the binding site of the enzyme.

Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents

In an effort to expand the structure-activity relationship of the natural anticancer compound piperlongumine, we have prepared sixteen novel piperlongumine derivatives with halogen or morpholine substituents at C2 and alkyl substituents at C7. Most of 2-halogenated piperlongumines showed potent in vitro activity against four cancer cells and modest selectivity for lung normal cells. The highly active anticancer compound 11h exhibited obvious ROS elevation and excellent in vivo antitumor potency with suppressed tumor growth by 48.58% at the dose of 2 mg/kg. The results indicated that halogen substituents as electrophilic group at C2 played an important role in increasing cytotoxicity.